These observations, together with results from a recent study reporting the inhibitory effect of the PI3K inhibitor PIK-75 on cell lines derived from cSCC metastases of the head and neck [59], strongly suggest that sensitivity to BYL719 should be further investigated in a panel of metastatic cSCC cells. Here, PIK3CD is linked to skin squamous cell carcinoma.